PD-1 and PARP Combination Therapy for Resistant Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for platinum-resistant and BRCA-negative cancers, often require high doses of individual therapies that can lead to toxicity and limited clinical benefits, necessitating a more effective combination therapy.
Innovation Solution
Administering a combination of therapies that inhibit PD-1 signaling and PARP, using agents such as pembrolizumab and niraparib, to reduce the effective dose and enhance treatment efficacy for cancers like ovarian, breast, and endometrial cancers, even in platinum-resistant and BRCA-negative cases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of individual therapies are used to treat platinum-resistant and BRCA-negative cancers, then treatment efficacy is improved, but toxicity increases
Solution Approach 1:
The patent combines anti-PD-1 therapy and anti-PARP therapy into a single treatment regimen. This combination allows the therapies to work synergistically, achieving tumor control with lower doses of each individual agent, thereby maintaining treatment efficacy while reducing the toxicity associated with high-dose monotherapies
2Reliability
If high doses of individual therapies are used to achieve clinical benefit, then treatment efficacy is improved, but the effective dose is limited by toxicity
Solution Approach 1:
By merging anti-PD-1 and anti-PARP therapies, the patent enables each agent to be administered at lower doses while achieving the same or better clinical benefit compared to high-dose monotherapy. The combination synergistically enhances tumor cell death through multiple mechanisms without exceeding the toxic dose limits of individual agents
Data Source
AI summary
The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.